Startseite Cross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Cross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia

  • Thomas P. Smith EMAIL logo , Sinead Kelly und Michael N. Fahie-Wilson
Veröffentlicht/Copyright: 17. Juni 2022
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Objectives

Macroprolactin cross-reacts in immunoassays for prolactin causing apparent hyperprolactinaemia (macroprolactinaemia) and consequent misdiagnosis and mismanagement of patients.

Methods

We determined the prevalence of macroprolactinaemia using prolactin immunoassays with reported “high” (Tosoh) or “low” cross-reactivity (Roche) with macroprolactin. We additionally modelled the effects of increasing the screening threshold on workload and sensitivity in the detection of macroprolactinaemia.

Results

A review of routine requests for prolactin received in a 12 month period identified 670 sera with hyperprolactinaemia (Tosoh assay). Treatment with polyethylene glycol (PEG) precipitation demonstrated normal levels of monomeric prolactin in 165 sera (24.6%) indicating macroprolactinaemia. In the macroprolactinaemic cohort, total prolactin levels were lower with the Roche assay (473 ± 132 mU/L; mean ± SD) compared to the Tosoh assay (683 ± 217 mU/L), p < 0.005. The prevalence of macroprolactinaemia was also lower with the Roche assay (6.2%). The number of samples that required screening for macroprolactinaemia fell by 14% when Roche gender specific total prolactin reference limits were applied. Use of a higher screening threshold (700 mU/L) reduced the screening workload considerably (Roche by 45%, Tosoh by 37%) however, the sensitivity of detection of macroprolactinaemia decreased markedly (Roche 90%, Tosoh 59%).

Conclusions

Macroprolactin interferes in both Tosoh and Roche prolactin immunoassays. Use of an assay with a relatively low cross reactivity with macroprolactin, e.g. Roche, will lead to a modest reduction in the screening workload. Increasing the screening threshold above the upper limit of the assay reference interval will also reduce the screening workload but leads to disproportionate increases in the number of cases of macroprolactinaemia which are missed.


Corresponding author: Thomas P. Smith, Department of Investigative Endocrinology, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland, Phone: 00-353-221-4629, E-mail:

  1. Research funding: Some reagents for this study were kindly provided by Roche Diagnostics.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not Applicable.

  5. Ethical approval: Approval for this study was obtained from the Research Ethics Committee, St. Vincent’s University Hospital.

References

1. Fahie-Wilson, M, Smith, TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27(5):725–42, https://doi.org/10.1016/j.beem.2013.07.002.Suche in Google Scholar

2. Wallace, IR, Satti, N, Courtney, CH, Leslie, H, Bell, PM, Hunter, SJ, et al.. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab 2010;95(7):3268–71, https://doi.org/10.1210/jc.2010-0114.Suche in Google Scholar

3. McKenna, TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf) 2009;71(4):466–9, https://doi.org/10.1111/j.1365-2265.2009.03577.x.Suche in Google Scholar

4. Hattori, N, Aisaka, K, Shimatsu, A. A possible cause of the variable detectability of macroprolactin by different immunoassay systems. Clin Chem Lab Med 2016;54:603–8. https://doi.org/10.1515/cclm-2015-0484.Suche in Google Scholar

5. Hattori, N, Ishihara, T, Saiki, Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009;71:702–8. https://doi.org/10.1111/j.1365-2265.2009.03570.x.Suche in Google Scholar

6. Smith, TP, Suliman, AM, Fahie-Wilson, MN, McKenna, TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87:5410–5. https://doi.org/10.1210/jc.2001-011943.Suche in Google Scholar

7. Schneider, W, Marcovitz, S, Al-Shammari, S, Yago, S, Chevalier, S. Reactivity of macroprolactin in common automated immunoassays. Clin Biochem 2001;34:469–73. https://doi.org/10.1016/s0009-9120(01)00256-9.Suche in Google Scholar

8. Cavaco, B, Prazeres, S, Santos, MA, Sobrinho, LG, Leite, V. Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999;22:203–8. https://doi.org/10.1007/bf03343542.Suche in Google Scholar PubMed

9. Fahie-Wilson, MN. Detection of macroprolactin causing hyperprolactinemia in commercial assays for prolactin. Clin Chem 2000;46:2022–3. https://doi.org/10.1093/clinchem/46.12.2022.Suche in Google Scholar

10. de Soárez, PC, Souza, SC, Vieira, JG, Ferraz, MB. The effect of identifying macroprolactinemia on health-care utilization and costs in patients with elevated serum prolactin levels. Value Health 2009;12:930–4. https://doi.org/10.1111/j.1524-4733.2009.00563.x.Suche in Google Scholar PubMed

11. Gibney, J, Smith, TP, McKenna, TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005;62:633–43. https://doi.org/10.1111/j.1365-2265.2005.02243.x.Suche in Google Scholar

12. Suliman, AM, Smith, TP, Gibney, J, McKenna, TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504–9. https://doi.org/10.1373/49.9.1504.Suche in Google Scholar

13. Olukoga, AO, Dornan, TL, Kane, JW. Three cases of macroprolactinaemia. J R Soc Med 1999;92:342–4. https://doi.org/10.1177/014107689909200704.Suche in Google Scholar

14. Heaney, AP, Laing, I, Walton, L, Seif, MW, Beardwell, CG, Davis, JR. Misleading hyperprolactinaemia in pregnancy. Lancet 1999;353:720. https://doi.org/10.1016/s0140-6736(98)10183-6.Suche in Google Scholar

15. Guay, AT, Sabharwal, P, Varma, S, Malarkey, WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 1996;81:2512–4. https://doi.org/10.1210/jc.81.7.2512.Suche in Google Scholar

16. Overgaard, M, Pedersen, SM. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin Chem Lab Med 2017;55:1744–53. https://doi.org/10.1515/cclm-2016-0902.Suche in Google Scholar PubMed

17. Šostarić, M, Bokulić, A, Marijančević, D, Zec, I. Optimizing laboratory defined macroprolactin algorithm. Biochem Med (Zagreb) 2019;29:020706. https://doi.org/10.11613/bm.2019.020706.Suche in Google Scholar

18. Saleem, M, Martin, H, Coates, P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev 2018;39:3–16.Suche in Google Scholar

19. Che Soh, NAA, Yaacob, NM, Omar, J, Mohammed Jelani, A, Shafii, N, Tuan Ismail, TS, et al.. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Publ Health 2020;17:8199. https://doi.org/10.3390/ijerph17218199.Suche in Google Scholar PubMed PubMed Central

20. Vilar, L, Vilar, C, Albuquerque, JL, Thé, AC, Gadelh, P, Borges, T, et al.. The importance of routine screening for macroprolactin in symptomatic patients with idiopathic hyperprolactinemia. An Fac Med Olinda, Recife 2018;1:2. https://doi.org/10.56102/afmo.2018.6.Suche in Google Scholar

21. Fahie-Wilson, MN, Soule, SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252–8. https://doi.org/10.1177/000456329703400305.Suche in Google Scholar PubMed

22. Beltran, L, Fahie-Wilson, MN, McKenna, TJ, Kavanagh, L, Smith, TP. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673–81. https://doi.org/10.1373/clinchem.2008.105312.Suche in Google Scholar PubMed

23. Smith, TP, Fahie-Wilson, MN. Reporting of post-PEG prolactin concentrations: time to change. Clin Chem 2010;56:484–5. https://doi.org/10.1373/clinchem.2009.135210.Suche in Google Scholar PubMed

24. Melmed, S, Casanueva, FF, Hoffman, AR, Kleinberg, DL, Montori, VM, Schlechte, JA, et al.. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88. https://doi.org/10.1210/jc.2010-1692.Suche in Google Scholar PubMed

25. Searell, C, Evans, C. Standards for the Investigation of Macroprolactinaemia. In: A.W.C.B.A. Group, editor. The Association of Clinical Biochemistry & Laboratory Medicine; 2012. Available from: https://www.acb.org.uk.Suche in Google Scholar

26. Whitehead, SJ, Cornes, MP, Ford, C, Gama, R. Reference ranges for serum total and monomeric prolactin for the current generation Abbott Architect assay. Ann Clin Biochem 2015;52:61–6. https://doi.org/10.1177/0004563214547779.Suche in Google Scholar PubMed

27. Casanueva, FF, Molitch, ME, Schlechte, JA, Abs, R, Bonert, V, Bronstein, MD, et al.. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–73. https://doi.org/10.1111/j.1365-2265.2006.02562.x.Suche in Google Scholar PubMed

28. Byrne, B, O’Shea, P, Barrett, P, Tormey, W. The Beckman DxI 800 prolactin assay demonstrates superior specificity for monomeric prolactin. Clin Chem Lab Med 2010;48:205–8. https://doi.org/10.1515/cclm.2010.038.Suche in Google Scholar PubMed

29. Ellis, MJ, Livesey, JH, Soule, SG. Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay. Clin Biochem 2006;39:1028–34. https://doi.org/10.1016/j.clinbiochem.2006.06.003.Suche in Google Scholar PubMed

30. Jassam, NF, Paterson, A, Lippiatt, C, Barth, JH. Macroprolactin on the advia centaur: experience with 409 patients over a three-year period. Ann Clin Biochem 2009;46:501–4. https://doi.org/10.1258/acb.2009.009059.Suche in Google Scholar PubMed

31. Vieira, JG, Tachibana, TT, Ferrer, CM, Sá, J, Biscolla, RP, Hoff, AO, et al.. Hyperprolactinemia: new assay more specific for the monomeric form does not eliminate screening for macroprolactin with polyethylene glycol precipitation. Arq Bras Endocrinol Metabol 2010;54:856–7. https://doi.org/10.1590/s0004-27302010000900013.Suche in Google Scholar PubMed

32. Ellis, MJ, Reed, MR, Livesey, JH. Cross-reactivities of macroprolactin and big-prolactin in three commercial immunoassays for prolactin: a chromatographic analysis. Clin Biochem 2007;40:1285–90. https://doi.org/10.1016/j.clinbiochem.2007.08.002.Suche in Google Scholar PubMed

33. Fahie-Wilson, M, Bieglmayer, C, Kratzsch, J, Nusbaumer, C, Roth, HJ, Zaninotto, M, et al.. Roche Elecsys Prolactin II assay: reactivity with macroprolactin compared with eight commercial assays for prolactin and determination of monomeric prolactin by precipitation with polyethylene glycol. Clin Lab 2007;53:485–92.Suche in Google Scholar

34. Jeffcoate, SL, Bacon, RR, Beastall, GH, Diver, MJ, Franks, S, Seth, J. Assays for prolactin: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 1986;23:638–51. https://doi.org/10.1177/000456328602300603.Suche in Google Scholar PubMed

35. Cattaneo, FA, Fahie-Wilson, MN. Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. case report. J Neurosurg 2001;95:334–7. https://doi.org/10.3171/jns.2001.95.2.0334.Suche in Google Scholar PubMed

36. Hattori, N, Adachi, T, Ishihara, T, Shimatsu, A. The natural history of macroprolactinaemia. Eur J Endocrinol 2012;166:625–9. https://doi.org/10.1530/eje-11-1007.Suche in Google Scholar

Received: 2022-05-12
Accepted: 2022-06-02
Published Online: 2022-06-17
Published in Print: 2022-08-26

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Clinical Chemistry and Laboratory Medicine: enjoying the present and assessing the future
  4. Rethinking internal quality control: the time is now
  5. Review
  6. Multi-omics analysis from archival neonatal dried blood spots: limitations and opportunities
  7. Opinion Papers
  8. ‘Penelope test’: a practical instrument for checking appropriateness of laboratory tests
  9. Interference by macroprolactin in assays for prolactin: will the In Vitro Diagnostics Regulation lead to a solution at last?
  10. EFLM Paper
  11. Efficiency, efficacy and subjective user satisfaction of alternative laboratory report formats. An investigation on behalf of the Working Group for Postanalytical Phase (WG-POST), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
  12. General Clinical Chemistry and Laboratory Medicine
  13. Cross-reactivity in assays for prolactin and optimum screening policy for macroprolactinaemia
  14. Repository of intra- and inter-run variations of quantitative autoantibody assays: a European multicenter study
  15. Stability of direct renin concentration and plasma renin activity in EDTA whole blood and plasma at ambient and refrigerated temperatures from 0 to 72 hours
  16. Comparison of four different immunoassays and a rapid isotope-dilution liquid chromatography-tandem mass spectrometry assay for serum folate
  17. Analytical quality specifications in semen analysis according to the state of the current methodologies
  18. Reference Values and Biological Variations
  19. Short-term biological variation study of plasma hemophilia and thrombophilia parameters in a population of apparently healthy Caucasian adults
  20. First morning voided urinary gonadotropins in children: verification of method performance and establishment of reference intervals
  21. Derivation of sex and age-specific reference intervals for clinical chemistry analytes in healthy Ghanaian adults
  22. Cancer Diagnostics
  23. Serum free light chain analysis: persisting limitations with new kids on the block
  24. Cardiovascular Diseases
  25. Age partitioned and continuous upper reference limits for Ortho VITROS High Sensitivity Troponin I in a healthy paediatric cohort
  26. The predictive value of hemoglobin to creatinine ratio for contrast-induced nephropathy in percutaneous coronary interventions
  27. Infectious Diseases
  28. Health technology assessment to employ COVID-19 serological tests as companion diagnostics in the vaccination campaign against SARS-CoV-2
  29. Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay
  30. Presepsin levels in neonatal cord blood are not influenced by maternal SARS-CoV-2 infection
  31. Letters to the Editors
  32. How to evaluate fixed clinical QC limits vs. risk-based SQC strategies
  33. Reply to Westgard et al.: ‘Keep your eyes wide … as the present now will later be past’*
  34. Platelet phagocytosis by monocytes
  35. Early detection of Candida parapsilosis in peripheral blood as a result of a peripheral blood smear performed after cytographic changes on the Beckman Coulter UniCel DxH 800 hematology
  36. Pseudo-erythroblastosis on Sysmex XN hematology analyzers: a clue to Candida sepsis. Case report and literature review
  37. Covert poisoning with difenacoum: diagnosis and follow-up difficulties
  38. Comparison of Sebia Capillarys 3-OCTA with the Tosoh Bioscience HLC®-723G8 method for A1C testing with focus on analytical interferences and variant detection
Heruntergeladen am 18.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2022-0459/html
Button zum nach oben scrollen